InvestSMART

Zelira Therapeutics Limited (ASX:ZLD)

ALERT: Price-sensitive ASX Announcement for ZLD
Current share price for ZLD : $0.500 0.09 (21.95%)+
Announcement
Release
30 Jul 2025 4:29PM
Price at Release
$0.410
Full Release
download
Summary
Zelira Therapeutics Limited (ZLD) released its Quarterly Activities Report and Appendix 4C Cash Flow Report for the quarter ending March 31, 2024. The report highlights ongoing business developments, including progress in clinical trials, the launch of new products, continued revenue generation from existing products, and several key collaborations. Zelira continued to advance its strategic focus on neuroscience and cannabinoid-based therapeutics, reported operational achievements such as partnerships and manufacturing agreements, and outlined financials including cash position, receipts, and expenditure. The company also provided an overview of future plans and stated its commitment to delivering innovative health solutions.
Key Points
  • Zelira Therapeutics Limited reported its quarterly activities and cash flows for the period ending March 31, 2024.
  • Ongoing progress was made in clinical trials and the launch of new cannabinoid-based therapeutics.
  • The company maintained revenue streams from its existing product portfolio.
  • Key collaborations and partnerships were advanced to support research and commercialization efforts.
  • Zelira’s strategic focus continues to be on neuroscience and cannabinoid-based therapeutics.
  • Operational achievements included new product development and manufacturing agreements.
  • The cash flow report detailed receipts, expenditures, and the company’s cash position.
  • Zelira expressed confidence in its growth strategy and outlined future business priorities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.